{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:58:44Z","timestamp":1791849524675,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Italian Diabetes Society"},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40618-021-01501-y","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T03:41:15Z","timestamp":1610422875000},"page":"1879-1889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care"],"prefix":"10.1007","volume":"44","author":[{"given":"M. L.","family":"Morieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Vitturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Avogaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-2097","authenticated-orcid":false,"given":"G. P.","family":"Fadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DARWIN-T2D Network of the Italian Diabetes Society","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Consoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Formoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achiropita","family":"Pucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Sesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Andreozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Zavaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"DeiCas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Felace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Li Volsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Buzzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Leto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian","family":"Pio Sorice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carlo Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Duratorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivano","family":"Franzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Silvia Morpurgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Querci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Boemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Aimaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Karamouzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Cavalot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Cazzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvestre","family":"Cervone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Devangelio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lamacchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Di Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Frittitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Piro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Chianetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Mannina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Anichini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Penno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Solini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fattor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Bonora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cigolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Lapolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Cristiano Chilelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalino","family":"Simioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Frison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Vinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"issue":"5","key":"1501_CR1","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2337\/dc06-2247","volume":"30","author":"G Targher","year":"2007","unstructured":"Targher G et al (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30(5):1212\u20131218","journal-title":"Diabetes Care"},{"issue":"6","key":"1501_CR2","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.jhep.2020.07.018","volume":"73","author":"S Rodr\u00edguez-Tajes","year":"2020","unstructured":"Rodr\u00edguez-Tajes S, Pocurull A, Castillo J, Casanova G, Vega L, Lens S, Mari\u00f1o Z, Londo\u00f1o MC, Forner A, Torres F, Forns X (2020) Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions in the near future. J Hepatol 73(6):1360\u20131367","journal-title":"J Hepatol"},{"issue":"12","key":"1501_CR3","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.2337\/diabetes.54.12.3541","volume":"54","author":"G Targher","year":"2005","unstructured":"Targher G et al (2005) Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54(12):3541\u20133546","journal-title":"Diabetes"},{"issue":"3","key":"1501_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00125-007-0897-4","volume":"51","author":"G Targher","year":"2008","unstructured":"Targher G et al (2008) Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative\/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 51(3):444\u2013450","journal-title":"Diabetologia"},{"issue":"6","key":"1501_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee QM, Targher G, Day CP (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10(6):330\u2013344","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1501_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/1060028020935105","volume":"55","author":"JA Dougherty","year":"2020","unstructured":"Dougherty JA, Guirguis E, Thornby KA (2020) A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease. Ann Pharmacother 55:65\u201379","journal-title":"Ann Pharmacother"},{"issue":"1 Suppl","key":"1501_CR7","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62(1 Suppl):S47-64","journal-title":"J Hepatol"},{"key":"1501_CR8","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016. 64(6): 1388\u2013402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"1501_CR9","doi-asserted-by":"publisher","first-page":"108358","DOI":"10.1016\/j.diabres.2020.108358","volume":"167","author":"S Ciardullo","year":"2020","unstructured":"Ciardullo S, Sala I, Perseghin G (2020) Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005\u20132016. Diabetes Res Clin Pract 167:108358","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"1501_CR10","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/apt.12963","volume":"40","author":"L Fedchuk","year":"2014","unstructured":"Fedchuk L et al (2014) Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 40(10):1209\u20131222","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"1501_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH et al (2010) Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 42(7):503\u2013508","journal-title":"Dig Liver Dis"},{"issue":"4","key":"1501_CR12","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00330-011-2326-9","volume":"22","author":"B Guiu","year":"2012","unstructured":"Guiu B et al (2012) Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy. Eur Radiol 22(4):855\u2013863","journal-title":"Eur Radiol"},{"issue":"12","key":"1501_CR13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.numecd.2017.08.001","volume":"27","author":"GP Fadini","year":"2017","unstructured":"Fadini GP et al (2017) Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): a multicenter retrospective nationwide Italian study and crowdsourcing opportunity. Nutr Metab Cardiovasc Dis 27(12):1089\u20131097","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"7","key":"1501_CR14","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1111\/dom.13280","volume":"20","author":"GP Fadini","year":"2018","unstructured":"Fadini GP et al (2018) Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. Diabetes Obes Metab 20(7):1781\u20131786","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1501_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612","journal-title":"Ann Intern Med"},{"issue":"2","key":"1501_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/dom.13508","volume":"21","author":"GP Fadini","year":"2019","unstructured":"Fadini GP et al (2019) Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: a multicentre retrospective study. Diabetes Obes Metab 21(2):252\u2013260","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1501_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 73(1):202\u2013209","journal-title":"J Hepatol"},{"issue":"1","key":"1501_CR18","doi-asserted-by":"publisher","first-page":"e000904","DOI":"10.1136\/bmjdrc-2019-000904","volume":"8","author":"S Ciardullo","year":"2020","unstructured":"Ciardullo S et al (2020) Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diabetes Res Care 8(1):e000904. https:\/\/doi.org\/10.1136\/bmjdrc-2019-000904","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"1501_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/MCG.0000000000000905","volume":"52","author":"A Singh","year":"2018","unstructured":"Singh A et al (2018) The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 2 diabetic patients. J Clin Gastroenterol 52(3):268\u2013272","journal-title":"J Clin Gastroenterol"},{"key":"1501_CR20","doi-asserted-by":"crossref","unstructured":"Grecian SM et al (2020) Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study. Liver Int","DOI":"10.1111\/liv.14590"},{"key":"1501_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.diabet.2019.12.007","volume":"46","author":"A Mantovani","year":"2020","unstructured":"Mantovani A et al (2020) Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes Metab 46:427\u2013441","journal-title":"Diabetes Metab"},{"issue":"2","key":"1501_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/dmrr.2713","volume":"32","author":"W Tang","year":"2016","unstructured":"Tang W et al (2016) Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. Diabetes Metab Res Rev 32(2):200\u2013216","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"1501_CR23","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2337\/dc18-1569","volume":"42","author":"A Latva-Rasku","year":"2019","unstructured":"Latva-Rasku A et al (2019) The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients. Diabetes Care 42(5):931\u2013937","journal-title":"Diabetes Care"},{"issue":"8","key":"1501_CR24","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS et al (2018) Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care 41(8):1801\u20131808","journal-title":"Diabetes Care"},{"issue":"6","key":"1501_CR25","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1111\/jdi.13279","volume":"11","author":"T Kinoshita","year":"2020","unstructured":"Kinoshita T et al (2020) Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study. J Diabetes Investig 11(6):1612\u20131622","journal-title":"J Diabetes Investig"},{"issue":"7","key":"1501_CR26","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/dom.14004","volume":"22","author":"L Johansson","year":"2020","unstructured":"Johansson L et al (2020) Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. Diabetes Obes Metab 22(7):1094\u20131101","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1501_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/dom.13907","volume":"22","author":"A Gastaldelli","year":"2020","unstructured":"Gastaldelli A et al (2020) Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes Obes Metab 22(3):393\u2013403","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1501_CR28","doi-asserted-by":"publisher","first-page":"e00131","DOI":"10.1002\/edm2.131","volume":"3","author":"V Mittag-Roussou","year":"2020","unstructured":"Mittag-Roussou V et al (2020) Noninvasive monitoring of liver fat during treatment with GLP-1 analogues and SGLT-2 inhibitors in a real-world setting. Endocrinol Diabetes Metab 3(3):e00131","journal-title":"Endocrinol Diabetes Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01501-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01501-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01501-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T03:35:43Z","timestamp":1670729743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01501-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1501"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01501-y","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"28 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MLM received lecture or advisory fees or grant support from Mylan, SlaPharma, Amryt Pharma and Servier. AA received research grants, lecture or advisory board fees from Merck Sharp & Dome, AstraZeneca, Novartis, Boeringher-Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Lilly, Servier, and Takeda. GPF received lecture fees or grant support from Abbott, AstraZeneca, Boehringer, Lilly, Merck-Sharp-Dome, Mundipharma, Novartis, Novo Nordisk, Sanofi, Servier. GT does not have any competing interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Ethical Committees of all participating centers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study used anonymous data and, based on National and International regulations, a waiver was applied to the requirement for the patient\u2019s informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}